MicuRx(SH:688373) Zhong Guo Ji Jin Bao·2025-09-25 02:20Core Viewpoint - The largest shareholder of Amgen Pharmaceuticals, Genie Pharma, has initiated a strong counteraction by proposing the removal of the chairman and two other directors, while also publicly soliciting voting rights to oppose several resolutions at the upcoming shareholder meeting [1][3]. Group 1: Shareholder Actions - Genie Pharma voted against multiple resolutions, including a proposed capital increase, at the upcoming shareholder meeting scheduled for 2025 [1]. - Genie Pharma has proposed to remove ZHENGYU YUAN (袁征宇) and two other directors, citing their failure to fulfill their responsibilities and protect shareholder interests [3][11]. - The proposed new directors include individuals currently associated with BioVeda, a significant stakeholder in Genie Pharma [13]. Group 2: Financial Performance - Amgen Pharmaceuticals has reported significant financial losses since its inception, with cumulative losses exceeding 1.3 billion yuan from 2021 to 2024 [3]. - The company's revenue has shown growth, reaching 130 million yuan in 2024, but net profit losses have also increased, with losses of 441 million yuan reported for the same year [3]. - The company's cash flow from operations has been negative for several consecutive years, indicating ongoing financial distress [3][6]. Group 3: Corporate Governance Issues - Genie Pharma has raised concerns about the management's capabilities, stating that the company is at risk of delisting due to its high debt ratio of approximately 60% and a significant decline in net assets since its IPO [6]. - The company has faced delays in its IPO fundraising projects, which has adversely affected its operational performance [6][7]. - There are allegations of poor judgment regarding strategic partnerships, particularly with Haiqing Pharmaceuticals, which has faced regulatory penalties [8][9][10].